Genetic susceptibility to coronary artery disease: From promise to progress

Nature Reviews Genetics

Volumn 7, Issue 3, 2006, Pages 163-173

  Watkins, Hugh ^a   Farrall, Martin ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUKOTRIENE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METALLOPROTEINASE; PROTEIN ALOX5; PROTEIN ALOX5AP; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR 1; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROTIC PLAQUE; CAUSE OF DEATH; CHROMOSOME 1; CHROMOSOME 3; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOME; HAPLOTYPE; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNITY; INDUSTRIALIZATION; INFLAMMATION; LIFESTYLE; LIPID METABOLISM; MOLECULAR GENETICS; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; THROMBOSIS;

ANIMALS; CORONARY ARTERIOSCLEROSIS; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; INFLAMMATION; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

EID: 33644840046     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg1805     Document Type: Review

References (84)

1. Mackay, J. & Mensah, C. (eds) The Atlas of Heart Disease and Stroke (WHO, Geneva, Switzerland, 2004).
2. Lusis, A. J., Mar, R. & Pajukanta, P. Genetics of atherosclerosis. Annu. Rev. Genomics Hum. Genet. 5, 189-218 (2004).
3. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
4. Zdravkovic, S. et al. Heritability of death from coronary heart disease: a 36-year follow-up of 20,966 Swedish twins. J. Intern. Med. 252, 247-254 (2002).
5. Wright, A., Charlesworth, B., Rudan, I., Carothers, A. & Campbell, H. A polygenic basis for late-onset disease. Trends Genet. 19, 97-106 (2003).
6. Myers, R. H., Kiely, D. K., Cupples, L. A. & Kannel, W. B. Parental history is an independent risk factor for coronary artery disease:the Framingham study. Am. Heart J. 120, 963-969 (1990).
7. Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847 (1998).
8. Lloyd-Jones, D. M. et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 291, 2204-2211 (2004).
9. Assmann, G., Cullen, P. & Schulte, H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105, 310-315 (2002).
10. Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937-952 (2004).
11. Weiss, K. M. & Terwilliger, J. D. How many diseases does it take to map a gene with SNPs? Nature Genet. 26, 151-157 (2000).
12. Cohen, J. C. et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305, 869-872 (2004).
13. Rudan, I. et al. Inbreeding and risk of late onset complex disease. J. Med. Genet. 40, 925-932 (2003).
14. Lohmueller, K. E., Pearce, C. L., Pike, M., Lander, E. S. & Hirschhorn, J. N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nature Genet. 33, 177-182 (2003).
15. Wang, L., Fan, C., Topol, S. E., Topol, E. J. & Wang, Q. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 302, 1578-1581 (2003).
16. Bhagavatula, M. R. et al. Transcription factor MEF2A mutations in patients with coronary artery disease. Hum. Mol. Genet. 13, 3181-3188 (2004).
17. Gonzalez, P. et al. The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction. J. Med. Genet. 15 Jun 2005 [epub ahead of print].
18. Weng, L. et al. Lack of MEF2A mutations in coronary artery disease. J. Clin. Invest. 115, 1016-1020 (2005).
19. Helgadottir, A. et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nature Genet. 36, 233-239 (2004). A landmark positional cloning study, as it was the first to use linkage, linkage-disequilibrium mapping and functional studies to identify a CAD-susceptibility gene.
20. Spanbroek, R. et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl Acad. Sci. USA 100, 1238-1243 (2003).
21. Mehrabian, M. et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 91, 120-126 (2002).
22. Aiello, R. J. et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler. Thromb. Vasc. Biol. 22, 443-449 (2001).
23. Dwyer, J. H. et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 350, 29-37 (2004).
24. Danesh, J. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397 (2004).
25. Paul, A. et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109, 647-655 (2004).
26. Fletcher, L. Genomics companies shop around for chemical expertise. Nature Biotechnol. 22, 137-138 (2004).
27. Broeckel, U. et al. A comprehensive linkage analysis for myocardial infarction and its related risk factors. Nature Genet 30, 210-214 (2002).
28. Wang, Q. et al. Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. Am. J. Hum. Genet 74, 262-271 (2004).
29. Hauser, E. R. et al. A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study. Am. J. Hum. Genet. 75, 436-447 (2004).
30. Harrap, S. B. et al. Genome-wide linkage analysis of the acute coronary syndrome suggests a locus on chromosome 2. Arterioscler. Thromb. Vasc. Biol. 22, 874-878 (2002).
31. Chiodini, B. D. & Lewis, C. M. Meta-analysis of 4 coronary heart disease genome-wide linkage studies confirms a susceptibility locus on chromosome 3q. Arterioscler. Thromb. Vasc. Biol. 23, 1863-1868 (2003).
32. Campbell, L. A. & Kuo, C. C. Chlamydia pneumoniae - an infectious risk factor for atherosclerosis? Nature Rev. Microbiol. 2, 23-32 (2004).
33. LeVan, T. D. et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J. Immunol. 167, 5838-5844 (2001).
34. Arroyo-Espliguero, R., Avanzas, P., Jeffery, S. & Kaski, J. C. CD14 and toll-like receptor 4: a link between infection and acute coronary events? Heart 90, 983-988 (2004).
35. Pasterkamp, G. J., van Keulen, K. & de Kleijn, D. P. V. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur. J. Clin. Invest 34, 328-334 (2004).
36. Kiechl, S. et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 47, 185-192 (2002).
37. Ameziane, N. et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler. Thromb. Vasc. Biol. 23, e61-e64 (2003).
38. Boekholdt, S. M. et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 107, 2416-2132 (2003).
39. Michelsen, K. S. et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl Acad. Sci. USA. 101, 10679-10684 (2004).
40. Edfeldt, K. et al. Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. Eur. Heart J. 25, 1447-1453 (2004).
41. Yang, I.A., Holloway, J. W. & Ye, S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis 170, 187-190 (2003).
42. Colhoun, H. M., McKeigue, P. M. & Davey Smith, G. Problems of reporting genetic associations with complex outcomes. Lancet 361, 865-872 (2003).
43. Keavney, B. et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 355, 434-442 (2000).
44. Hirschhorn, J. N. & Daly, M. J. Genome-wide association studies for common diseases and complex traits. Nature Rev. Genet. 6, 95-108 (2005).
45. Farrall, M. & Morris, A. P. Gearing up for genome-wide gene-association studies. Hum. Mol. Genet. 14: (Suppl. 2), R157-R162 (2005).
46. Risch, N. & Merikangas, K. The future of genetic studies of complex human diseases. Science 273, 1516-1517 (1996).
47. Ozaki, K. et al. Functional SNPs in the lymphotoxin-α gene that are associated with susceptibility to myocardial infarction. Nature Genet. 32, 650-654 (2002). A pioneering genome-scale gene-association study for susceptibility to myocardial infarction that identified causal variants in the LTA gene.
48. Iwanaga, Y. et al. Association analysis between polymorphisms of the lymphotoxin-α gene and myocardial infarction in a Japanese population. Atherosclerosis 172, 197-198 (2004).
49. Yamada, A. et al. Lack of association of polymorphisms of the lymphotoxin α gene with myocardial infarction in Japanese. J. Mol. Med. 82, 477-483 (2004).
50. The PROCARDIS Consortium. A trio family study showing association of the lymphotoxin-α N26 (804A) allele with coronary artery disease. Eur. J. Hum. Genet. 12, 770-774 (2004).
51. Knight, J. C., Keating, B. J., Rockett, K. A. & Kwiatkowski, D. P. In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nature Genet. 33, 469-475 (2003).
52. Knight, J. C., Keating, B. J. & Kwiatkowski, D. P. Allele-specific repression of lymphotoxin-α by activated B cell factor-1. Nature Genet. 36, 394-399 (2004).
53. Schreyer, S. A., Vick, C. M. & LeBoeuf, R. C. Loss of lymphotoxin-α but not tumor necrosis factor-α reduces atherosclerosis in mice. J. Biol. Chem. 277, 12364-12368 (2002).
54. Ozaki, K. et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-α secretion in vitro. Nature 429, 72-75 (2004).
55. Cullen, P. et al. Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler. Thromb. Vasc. Biol. 23, 535-542 (2003).
56. Wang, X. et al. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nature Genet. 37, 365-372 (2005).
57. Austin, M. A., Hokanson, J. E. & Edwards, K. L. Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol. 81, 7B-12B (1998).
58. Rees, A., Shoulders, C. C., Stocks, J., Galton, D. J. & Baralle, F. E. DNA polymorphism adjacent to the human apolipoprotein A1 gene: relationship to hypertriglyceridemia. Lancet 1, 444-446 (1983).
59. van Dijk, K. W., Rensen, P. C., Voshol, P. J. & Havekes, L. M. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr. Opin. Lipidol. 15, 239-246 (2004).
60. Pennacchio, L. A. et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294, 169-173 (2001). An exemplary comparative genomics study that identified and characterized a novel apolipoprotein which was later implicated in human dyslipidaemia.
61. Shoulders, C. C., Jones, E. L. & Naoumova, R. P. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum. Mol. Genet. 13, R149-R160 (2004).
62. Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L. & Motulsky, A. G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52, 1544-1568 (1973).
63. Austin, M. A. et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 101, 2777-2782 (2000).
64. Wojciechowski, A. P. et al. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CII-AIV gene cluster on chromosome 11q23-q24. Nature 349, 161-164 (1991).
65. Castellani, L. W. et al. Mapping a gene for combined hyperlipidaemia in a mutant mouse strain. Nature Genet. 18, 374-377 (1998).
66. Bodnar, J. S. et al. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nature Genet. 30, 110-116 (2002).
67. Pajukanta, P. et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nature Genet. 36, 371-376 (2004). Following up on earlier linkage to chromosome 1q, gene-association studies excluded a candidate gene (TXNIP) that was implicated in mouse studies and instead identified a novel susceptibility gene that has a conserved intronic regulatory element.
68. Coon, H. et al. TXNIP gene not associated with familial combined hyperlipidemia in the NHLBI Family Heart Study. Atherosclerosis. 174, 357-362 (2004).
69. Putt, W. et al. Variation in USF1 shows haplotype effects, gene:gene and gene:environment associations with glucose and lipid parameters in the European Atherosclerosis Research Study II. Hum. Mol. Genet. 13, 1587-1597 (2004).
70. Naukkarinen, J. et al. USF1 and dyslipidemias: converging evidence for a functional intronic variant. Hum. Mol. Genet. 14, 2595-2605 (2005).
71. Farrall, M. Quantitative genetic variation: a post-modern view. Hum. Mol. Genet. 13, R1-R7 (2004).
72. Morley, M. et al. Genetic analysis of genome-wide variation in human gene expression. Nature 430, 743-747 (2004).
73. Swanberg, M. et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nature Genet. 37, 486-494 (2005).
74. Marchini, J., Cardon, L. R., Phillips, M. S. & Donnelly, P. The effects of human population structure on large genetic association studies. Nature Genet. 36, 512-517 (2004).
75. Keavney, B. Commentary: Katan's remarkable foresight: genes and causality 18 years on. Int. J. Epidemiol. 33, 11-14 (2004).
76. Benjamin, E. J. et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 109, 613-619 (2004).
77. Mitchell, G. F. et al. Heritability and a genome-wide linkage scan for arterial stiffness, wave reflection, and mean arterial pressure: the Framingham Heart Study. Circulation 112, 194-199 (2005).
78. Jansen, R. C. & Nap, J. P. Genetical genomics: the added value from segregation. Trends Genet. 17, 388-391 (2001).
79. Schadt, E. E. et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nature Genet. 37, 710-717 (2005).
80. Jansen, R. C. & Nap, J. P. Regulating gene expression: surprises still in store. Trends Genet. 20, 223-225 (2004).
81. Cervino, A.C. et al. Integrating QTL and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene for plasma cholesterol levels. Genomics. 86, 505-517 (2005).
82. Mehrabian, M. et al. Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nature Genet. 37, 1224-1233 (2005).
83. Helgadottir, A. et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nature Genet. 38, 68-74 (2006).
84. Choudhury, R. P. Fuster, V. & Fayad, Z. A. Molecular, cellular and functional imaging of atherothrombosis. Nature Rev. Drug Discov. 3, 913-925 (2004).